Dr Roger Liang

Lecturer

School of Biomedical Sciences and Pharmacy (Pharmacy and Experimental Pharmacology)

Career Summary

Biography

Dr Liang was trained as a pharmaceutical scientist and has since developed well-equipped research capabilities and leadership in the cross-disciplinary field of advanced drug delivery and nanomedicine. Dr. Liang completed his PhD in Pharmacy from the University of Queensland. His doctoral research theme was to develop nanoparticulate delivery systems for subunit vaccines, which spanned a range of fields including medicinal chemistry, pharmaceutical formulation, and immunology. Toward the end of his PhD, Dr Liang started to engage in research at the interface between polymer science and drug delivery and had gained hands-on experience in a variety of polymerisation and bioconjugation techniques. Upon completion of PhD, Dr Liang took up a postdoctoral position at UQ to investigate the biological interactions and toxicity of precisely engineered nanoparticles. This research had led to some key fundamental discoveries that resulted in several publications in the premium journals including ACS Nano, Nature Nanotechnology, Nanomedicines etc. During this time, Dr Liang was also a research teaching academic at School of Pharmacy and committed to teaching pharmacy undergraduates. After that, Dr Liang joined the Centre for Advanced Macromolecular Design in University of New South Wales, and his research was to develop a platform technology for the efficient delivery of albendazole towards better anti-cancer treatment. In 2011, Dr Liang accepted a lecturer position to establish drug delivery research group at the School of Biomedical Science and Pharmacy in University of Newcastle.

Research Expertise
Dr Liang’s current research centres on advanced drug delivery and nanomedicine, which are at the interface of multidisciplinary fields including chemical & molecular engineering, materials science, chemistry, biotechnology and medicine. His research mainly involves developing novel biomaterials, utilizing self-assembly strategies to formulate biomaterials into desired nano-, micro- and macroscopic structures, and studying applications of these engineered structures for disease treatment and diagnosis.

Teaching Expertise
I mainly teach into pharmaceutics and pharmacy practice within Master of Pharmacy program. In addition, I also deliver guest lectures into Bachelor of Biomedical Science program in the field of drug delivery.





Qualifications

  • PhD, University of Queensland

Keywords

  • Biomaterials
  • Drug delivery
  • Nanomedicine
  • Pharmaceutics
  • Pharmacy Practice

Professional Experience

UON Appointment

Title Organisation / Department
Lecturer University of Newcastle
School of Biomedical Sciences and Pharmacy
Australia
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Journal article (21 outputs)

Year Citation Altmetrics Link
2016 Shargh VH, Hondermarck H, Liang M, 'Antibody-targeted biodegradable nanoparticles for cancer therapy', Nanomedicine, 11 63-79 (2016) [C1]

© 2016 Future Medicine Ltd.The use of nanotechnology has great potentials to revolutionize the future cancer diagnosis and therapy. In this context, various nanoparticles (NPs) h... [more]

© 2016 Future Medicine Ltd.The use of nanotechnology has great potentials to revolutionize the future cancer diagnosis and therapy. In this context, various nanoparticles (NPs) have been developed for targeted delivery of diagnostic/therapeutic agents to the tumor sites, which thus result in greater efficacy and much less side effects. The targeting property of NPs is often achieved by functionalizing their surface with tumor-specific ligands, such as antibodies, peptides, small molecules and oligonucleotides. In this review, we will discuss recent progress in the multifunctional design of antibody-targeted NPs with a special focus on liposomal, polymeric and protein-based delivery systems.

DOI 10.2217/nnm.15.186
Citations Scopus - 6Web of Science - 5
Co-authors Hubert Hondermarck
2016 Shargh VH, Hondermarck H, Liang M, 'Albumin hybrid nanoparticles loaded with tyrosine kinase A inhibitor GNF-5837 for targeted inhibition of breast cancer cell growth and invasion.', Int J Pharm, 515 527-534 (2016) [C1]
DOI 10.1016/j.ijpharm.2016.10.057
Co-authors Hubert Hondermarck
2015 Noorani L, Stenzel M, Liang R, Pourgholami MH, Morris DL, 'Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft model', Journal of Nanobiotechnology, 13 (2015) [C1]
DOI 10.1186/s12951-015-0082-8
2014 Jiang Y, Liang M, Svejkar D, Hart-Smith G, Lu H, Scarano W, Stenzel MH, 'Albumin-micelles via a one-pot technology platform for the delivery of drugs', Chemical Communications, 50 6394-6394 (2014) [C1]
DOI 10.1039/c4cc00616j
Citations Scopus - 10
2014 Noorani L, Pourgholami MH, Liang M, Morris DL, Stenzel M, 'Albendazole loaded albumin nanoparticles for ovarian cancer therapy', European Journal of Nanomedicine, 6 227-236 (2014) [C1]

© 2014 by De Gruyter 2014.Albendazole (ABZ), a well-established antiparasitic drug, has been shown to suppress tumor growth in a number of preclinical models of cancer. However, ... [more]

© 2014 by De Gruyter 2014.Albendazole (ABZ), a well-established antiparasitic drug, has been shown to suppress tumor growth in a number of preclinical models of cancer. However, the low solubility of ABZ limits its use as a systemic anticancer agent. To enable systemic administration, we have formulated ABZ into albumin nanoparticles with a size range of 200-300 nm, which were cross-linked with glutaraldehyde to stabilize the nanoparticles and to introduce pH-responsive features. Drug release studies demonstrated that about 20% of ABZ was released at neutral pH within a week in comparison to 70% at slightly acidic condition (pH 5). Cellular uptake studies using ovarian cancer cells indicated that nanoparticles were internalized efficiently within 1 h of incubation. Further, cell proliferation results demonstrated that albumin nanoparticles alone showed no cytotoxicity to both normal and cancer cells. In contrast, the drug-loaded nanoparticles exhibited cellular toxicity and high killing efficacy to cancer cells compared to normal cells. Collectively, our results suggest that these albumin nanoparticles may hold great potentials as ABZ carriers for cancer therapy.

DOI 10.1515/ejnm-2014-0026
Citations Scopus - 1
2013 Deng ZJ, Liang M, Toth I, Monteiro M, Minchin RF, 'Plasma protein binding of positively and negatively charged polymer-coated gold nanoparticles elicits different biological responses', Nanotoxicology, 7 314-322 (2013) [C1]
Citations Scopus - 41
2012 Yhaya F, Sutinah A, Gregory AM, Liang M, Stenzel MH, 'RAFT polymerization of vinyl methacrylate and subsequent conjugation via enzymatic thiol-ene chemistry', Journal of Polymer Science Part A: Polymer Chemistry, 50 4085-4093 (2012) [C1]
Citations Scopus - 7
2012 Lin I-C, Liang M, Liu T-Y, Jia Z, Monteiro M, Toth I, 'Effect of polymer grafting density on silica nanoparticle toxicity', Bioorganic and Medicinal Chemistry, 20 6862-6869 (2012) [C1]
Citations Scopus - 8
2012 Lin I-C, Liang M, Liu T-Y, Monteiro MJ, Toth I, 'Cellular transport pathways of polymer coated gold nanoparticles', Nanomedicine: Nanotechnology Biology and Medicine, 8 8-11 (2012) [C1]
Citations Scopus - 20
2012 Deng ZJ, Liang M, Toth I, Monteiro MJ, Minchin RF, 'Molecular Interaction of Poly(acrylic acid) Gold Nanoparticles with Human Fibrinogen', ACS Nano, 6 8962-8969 (2012) [C1]
Citations Scopus - 62
2011 Lin I-C, Liang M, Liu T-Y, Ziora ZM, Monteiro MJ, Toth I, 'Interaction of Densely Polymer-Coated Gold Nanoparticles with Epithelial Caco-2 Monolayers', Biomacromolecules, 12 1339-1348 (2011) [C1]
Citations Scopus - 29
2011 Deng ZJ, Liang M, Monteiro MJ, Toth I, Minchin RF, 'Nanoparticle-induced unfolding of fibrinogen promotes Mac-1 receptor activation and inflammation', Nature Nanotechnology, 6 39-44 (2011) [C1]
Citations Scopus - 343
2011 Yhaya F, Lim J, Kim Y, Liang M, Gregory AM, Stenzel MH, 'Development of Micellar Novel Drug Carrier Utilizing Temperature-Sensitive Block Copolymers Containing Cyclodextrin Moieties', Macromolecules, 44 8433-8445 (2011) [C1]
Citations Scopus - 45
2010 Liang M, Lin I-C, Whittaker MR, Minchin RF, Monteiro MJ, Toth I, 'Cellular uptake of densely packed polymer coatings on gold nanoparticles', ACS Nano, 4 403-413 (2010) [C1]
Citations Scopus - 87
2009 Wu SY, Putral LN, Liang M, Chang H-I, Davies NM, McMillan NAJ, '. Development of a novel method for formulating stable siRNA-loaded lipid particles for in vivo use', Pharmaceutical Research, 26 512-522 (2009) [C1]
Citations Scopus - 28
2008 Sarpietro MG, Micieli D, Pignatello R, Liang M, Toth I, Castelli F, 'Effect of variation in the chain number and length in modulating the interaction of immunogenic lipopeptide with biomembrane models', Thermochimica Acta, 471 14-19 (2008) [C1]
Citations Scopus - 4
2008 Liang M, Davies NM, Toth I, 'Increasing entrapment of peptides within poly(alkyl cyanoacrylate) nanoparticles prepared by interfacial polymerization of water-in-oil microemulsions', International Journal of Pharmaceutics, 362 141-146 (2008) [C1]
Citations Scopus - 13
2008 Koda Y, Liang M, Blanchfield JT, Toth I, 'In vitro stability and permeability studies of liposomal delivery systems for a novel lipophilic endomorphin 1 analogue', International Journal of Pharmaceutics, 356 37-43 (2008) [C1]
Citations Scopus - 19
2008 Liang M, Davies NM, Toth I, 'A novel method for preparing immune stimulating complexes (ISCOMs) by hydration of freeze-dried lipid matrix', European Journal of Pharmaceutics and Biopharmaceutics, 68 840-845 (2008) [C1]
Citations Scopus - 5
2006 Liang M, Davies NM, Blanchfield JT, Toth I, 'Particulate systems as adjuvants and carriers for peptide and protein antigen', Current Drug Delivery, 3 379-388 (2006) [C1]
Citations Scopus - 46
2005 Liang M, Davies NM, Toth I, 'Encapsulation of lipopeptides within liposomes: Effect of number of lipid chains, chain length and method of liposome preparation', International Journal of Pharmaceutics, 301 247-254 (2005) [C1]
Citations Scopus - 36
Show 18 more journal articles

Conference (5 outputs)

Year Citation Altmetrics Link
2015 Shargh VH, Hondermarck H, Liang M, 'ENHANCING THE EFFICACY OF TYROSINE KINASE INHIBITORS THROUGH BIO-POLYMERIC ALBUMIN HYBRID NANOPARTICLES IN BREAST CANCER', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
Co-authors Hubert Hondermarck
2014 Xu B, Wang H, Liang M, Yu C, Hu J, Cheng H, 'A detail enhancement and dynamic range adjustment algorithm for high dynamic range images', Proceedings of SPIE - The International Society for Optical Engineering (2014)

© 2014 SPIE.Although high dynamic range (HDR) images contain large amounts of information, they have weak texture and low contrast. What's more, these images are difficult to be ... [more]

© 2014 SPIE.Although high dynamic range (HDR) images contain large amounts of information, they have weak texture and low contrast. What's more, these images are difficult to be reproduced on low dynamic range displaying mediums. If much more information is to be acquired when these images are displayed on PCs, some specific transforms, such as compressing the dynamic range, enhancing the portions of little difference in original contrast and highlighting the texture details on the premise of keeping the parts of large contrast, are needed. To this ends, a multi-scale guided filter enhancement algorithm which derives from the single-scale guided filter based on the analysis of non-physical model is proposed in this paper. Firstly, this algorithm decomposes the original HDR images into base image and detail images of different scales, and then it adaptively selects a transform function which acts on the enhanced detail images and original images. By comparing the treatment effects of HDR images and low dynamic range (LDR) images of different scene features, it proves that this algorithm, on the basis of maintaining the hierarchy and texture details of images, not only improves the contrast and enhances the details of images, but also adjusts the dynamic range well. Thus, it is much suitable for human observation or analytical processing of machines.

DOI 10.1117/12.2068556
Citations Scopus - 1
2014 Shargh VH, Hondermarck H, Liang M, 'MULTIFUNCTIONAL NANOMEDICINES BASED ON ALBUMIN FOR TARGETED BREAST CANCER THERAPY', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Co-authors Hubert Hondermarck
2012 Zhao Y, Liang M, Kim Y, Tan X, Zhang L, Stenzel MH, 'Development of core-crosslinked micelles for drug delivery system', Advanced Materials Research (2012) [E1]
Citations Scopus - 1
2006 Liang MT, Hennessy T, Toth I, Davies NM, Hook S, 'Synthetic lipopeptides formulated in liposomes: Effect on their immune stimulatory capacity in vitro', Proceedings of the 2006 International Conference on Nanoscience and Nanotechnology, ICONN (2006)

Conjugation of antigenic peptides to lipoamino acids (LAA) has been shown to increase the membrane permeability of peptides and protects them from enzymatic degradation, but the r... [more]

Conjugation of antigenic peptides to lipoamino acids (LAA) has been shown to increase the membrane permeability of peptides and protects them from enzymatic degradation, but the resulting LAA-conjugated peptides were poorly soluble in both aqueous and organic solvents. To overcome the formulation issue and to further enhance the bioactivity, lipopeptide constructs (LAA-LCMV 33-41) have been encapsulated within liposomes with high entrapment efficiency. The purpose of this study was to assess the immune stimulatory capacity of these lipopeptides and their liposomal formulations. Because dendritic cells (DCs) play a key role as antigen-presenting cells in immune responses, the in vitro cellular activities of the lipopeptides and their liposomal formulations were tested by measuring the up-regulation of the surface markers CD80, CD86 and MHCII on DCs. We found that conjugation of lipoamino acid with peptide antigen enhanced its immune stimulatory capacity compared with the unmodified peptide. However, encapsulation of lipopeptides within liposomes appears to compromise their immuno-stimulatory capacity at least at a loading of 10%. © 2006 IEEE.

DOI 10.1109/ICONN.2006.340608
Show 2 more conferences
Edit

Grants and Funding

Summary

Number of grants 3
Total funding $162,864

Click on a grant title below to expand the full details for that specific grant.


20171 grants / $136,364

Novel epithelial targets and targeting strategies to prevent asthma exacerbations$136,364

Funding body: Asthma Australia

Funding body Asthma Australia
Project Team Doctor Nathan Bartlett, Conjoint Professor Peter Wark, Doctor Roger Liang, Professor Darryl Knight
Scheme National Research Program
Role Investigator
Funding Start 2017
Funding Finish 2018
GNo G1601217
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

20151 grants / $25,000

Improving the effectiveness of a new treatment for acute myeloid leukaemia (AML)$25,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Kathryn Skelding, Miss Mengna Chi, Doctor Nikki Verrills, Doctor Roger Liang
Scheme Project Grant
Role Investigator
Funding Start 2015
Funding Finish 2015
GNo G1600224
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

20141 grants / $1,500

4th Annual World Congress of Nanoscience and Technology, Qingdao, P.R.China, 23 - 31 October 2014$1,500

Funding body: University of Newcastle - Faculty of Health and Medicine

Funding body University of Newcastle - Faculty of Health and Medicine
Project Team Doctor Roger Liang
Scheme Travel Grant
Role Lead
Funding Start 2014
Funding Finish 2014
GNo G1400985
Type Of Funding Internal
Category INTE
UON Y
Edit

Research Supervision

Number of supervisions

Completed1
Current1

Total current UON EFTSL

PhD0.7

Current Supervision

Commenced Level of Study Research Title Program Supervisor Type
2016 PhD Novel Targeted Therapy for Airway Remodeling in Asthma PhD (Pharmacy), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor

Past Supervision

Year Level of Study Research Title Program Supervisor Type
2017 PhD Multifunctional Nanomedicines Based on Albumin for Targeted Breast Cancer Therapy PhD (Pharmacy), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
Edit

Dr Roger Liang

Position

Lecturer
School of Biomedical Sciences and Pharmacy
Faculty of Health and Medicine

Focus area

Pharmacy and Experimental Pharmacology

Contact Details

Email roger.liang@newcastle.edu.au
Phone (02) 4985 4959
Fax (02) 4921 7903

Office

Room MS117
Building Medical Science Building
Location Callaghan
University Drive
Callaghan, NSW 2308
Australia
Edit